Manufacturer record
Tas Med (India) Pvt.ltd: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
3 batches manufactured by Tas Med (India) Pvt.ltd (Himachal Pradesh) were declared Not of Standard Quality between October 2024 and October 2024. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
3 records linked to Tas Med (India) Pvt.ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Tablets, Divalproex Sodium SR Tablets 500 mg | TMT-0211Mfg 2024-06 · Exp 2026-05 | MISBRANDED The drug product Divalproex Sodium SR Tablets is official in the currect edition of IP 2022. and as required as per second schedule of the Drugs and cosmetics Act, 1940, the said drug product shall comply with the standards set out in the Indian Pharmacopoeia. But the designation IP in conjunctin with the official title Divalproex Sodium SR Tablets on the label of the drug product was not mentioned as an indication that the drug product purports to comply with IP standrds. Hence the drug product shall be deemed to be MISBRANDED DRUG as per Section 17 of the drug and Cosmetics Act 1940 as it not labeled in the prescribed mannerMisbranded | State Lab Drugs Control Laboratory, TelanganaState lab | Oct 2024 |
| Divalproex Sodium SR Tablets 500 mg | TMT-0164Mfg 2024-06 · Exp 2024-05 | MISBRANDED The drug product Divalproex Sodium SR Tablets is official in the currect edition of IP 2022. and as required as per second schedule of the Drugs and cosmetics Act, 1940, the said drug product shall comply with the standards set out in the Indian Pharmacopoeia. But the designation IP in conjunctin with the official title Divalproex Sodium SR Tablets on the label of the drug product was not mentioned as an indication that the drug product purports to comply with IP standrds. Hence the drug product shall be deemed to be MISBRANDED DRUG as per Section 17 of the drug and Cosmetics Act 1940 as it not labeled in the prescribed mannerMisbranded | State Lab Drugs Control Laboratory, TelanganaState lab | Oct 2024 |
| Divalproex Sodium SR Tablets | TMT-0165Mfg 2024-06 · Exp 2024-05 | MISBRANDED The drug product Divalproex Sodium SR Tablets is official in the currect edition of IP 2022. and as required as per second schedule of the Drugs and cosmetics Act, 1940, the said drug product shall comply with the standards set out in theMisbranded | State Lab Drugs Control Laboratory, TelanganaState lab | Oct 2024 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.